For research use only. Not for therapeutic Use.
VU0134992（Cat No.:I019022）is a small molecule compound that acts as a selective antagonist of the metabotropic glutamate receptor 4 (mGluR4). mGluR4 is a G-protein coupled receptor involved in neurotransmission and plays a role in various neurological conditions, including Parkinson’s disease, schizophrenia, and anxiety disorders. By selectively inhibiting mGluR4, VU0134992 has shown potential in modulating glutamatergic signaling pathways, which could offer therapeutic benefits for these conditions. Preclinical studies suggest that VU0134992 may help regulate motor function, reduce anxiety, and provide neuroprotective effects, making it a promising candidate for further clinical development.
| Catalog Number | I019022 |
| CAS Number | 755002-90-5 |
| Molecular Formula | C₂₀H₃₁BrN₂O₂ |
| Purity | ≥95% |
| Target | Potassium Channel |
| IUPAC Name | 2-(2-bromo-4-propan-2-ylphenoxy)-N-(2,2,6,6-tetramethylpiperidin-4-yl)acetamide |
| InChI | InChI=1S/C20H31BrN2O2/c1-13(2)14-7-8-17(16(21)9-14)25-12-18(24)22-15-10-19(3,4)23-20(5,6)11-15/h7-9,13,15,23H,10-12H2,1-6H3,(H,22,24) |
| InChIKey | OTTDLWFVHQYRDA-UHFFFAOYSA-N |
| SMILES | CC(C)C1=CC(=C(C=C1)OCC(=O)NC2CC(NC(C2)(C)C)(C)C)Br |
| Reference | [1]. Kharade SV, et al. Discovery, Characterization, and Effects on Renal Fluid and Electrolyte Excretion of the Kir4.1 Potassium Channel Pore Blocker, VU0134992. Mol Pharmacol. 2018 Aug;94(2):926-937. |
